Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease

K. Manoj, Suman L. Nayak, Ekta Gupta, Ashish Kataria, Shiv K. Sarin

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Background & Aims: There is scant data on use of sofosbuvir containing directly acting antiviral (DAA) regimens in chronic kidney disease (CKD) patients. Recently generic versions of DAAs have become available in low-income countries including India. The aim of this study was to study the efficacy and safety of generic sofosbuvir in combination with generic ribavirin, ledipasvir or daclatasvir in HCV-infected patients with CKD including patients with advanced CKD (CKD stage 4 or 5 with an estimated glomerular filtration rate (GFR) <30 mL/min or those on dialysis). Methods: Seventy-one CKD patients (76% male, 84.5% on maintenance haemodialysis, 23.9% cirrhosis) with HCV infection were included in the study. Full-dose sofosbuvir was used in combination with ribavirin (n = 26, for 24 weeks, 69.2% genotype 1, 30.8% genotype 3), ledipasvir (n = 26, for 12 weeks, all genotype 1) and daclatasvir (n = 19, for 12 weeks, all genotype 3). Results: Sustained virological response (SVR) (HCV RNA <12 IU/mL) at 12 weeks after stopping treatment was seen in 100% of the patients in all the 3 groups. At 24-week follow-up after end of therapy, 1 patient in sofosbuvir plus ledipasvir group relapsed. At 48-week follow-up after end of therapy, 1 more patient in sofosbuvir plus ribavirin group relapsed. Conclusion: Full-dose sofosbuvir-based DAA therapy using generics is highly effective for individuals with HCV infection and CKD including advanced CKD (CKD stage 4 or 5 with an e-GFR <30 mL/min or those on dialysis).

Original languageEnglish (US)
Pages (from-to)2137-2148
Number of pages12
JournalLiver International
Volume38
Issue number12
DOIs
StatePublished - Dec 2018
Externally publishedYes

Keywords

  • chronic kidney diseases
  • dialysis
  • direct-acting antiviral
  • hepatitis c
  • sofosbuvir

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease'. Together they form a unique fingerprint.

Cite this